# Northern Technologies International Corp: financial statements, quarterly

NTIC · Nasdaq · CIK 875582 · [Industrials](/sectors/industrials.md) · fiscal year ends Aug 31

Pages: [Overview](/companies/ntic.md) · [Financials](/companies/ntic/financials.md) · [Filings](/companies/ntic/filings.md) · [Insiders](/companies/ntic/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntic/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.7 d](/filings/0001171843-24-006440.md) | [20.2](/filings/0001171843-25-000165.md) | [20.8](/filings/0001171843-25-002130.md) | [20.7](/filings/0001171843-25-004413.md) | [23.3 d](/filings/0001171843-25-007481.md) | [21.3](/filings/0001171843-26-000136.md) | [19.1](/filings/0001171843-26-002340.md) | [21.5](/filings/0001171843-26-004548.md) | [22.3 d](/filings/0001171843-25-007481.md) | [23.3](/filings/0001171843-26-000136.md) | [22.0](/filings/0001171843-26-002340.md) | [24.2](/filings/0001171843-26-004548.md) |
| Cost of revenue | $m | [13.1 d](/filings/0001171843-24-006440.md) | [12.8](/filings/0001171843-25-000165.md) | [12.5](/filings/0001171843-25-002130.md) | [12.8](/filings/0001171843-25-004413.md) | [13.1 d](/filings/0001171843-25-007481.md) | [13.2](/filings/0001171843-26-000136.md) | [12.3](/filings/0001171843-26-002340.md) | [13.2](/filings/0001171843-26-004548.md) | [13.9 d](/filings/0001171843-25-007481.md) | [14.9](/filings/0001171843-26-000136.md) | [14.1](/filings/0001171843-26-002340.md) | [16.1](/filings/0001171843-26-004548.md) |
| Gross profit | $m | [7.6 d](/filings/0001171843-24-006440.md) | [7.3](/filings/0001171843-25-000165.md) | [8.3](/filings/0001171843-25-002130.md) | [7.9](/filings/0001171843-25-004413.md) | [10.2 d](/filings/0001171843-25-007481.md) | [8.2](/filings/0001171843-26-000136.md) | [6.8](/filings/0001171843-26-002340.md) | [8.3](/filings/0001171843-26-004548.md) | [8.5 d](/filings/0001171843-25-007481.md) | [8.4](/filings/0001171843-26-000136.md) | [7.9](/filings/0001171843-26-002340.md) | [8.1](/filings/0001171843-26-004548.md) |
| Research and development | $m | [1.3 d](/filings/0001171843-24-006440.md) | [1.1](/filings/0001171843-25-000165.md) | [1.2](/filings/0001171843-25-002130.md) | [1.2](/filings/0001171843-25-004413.md) | [1.2 d](/filings/0001171843-25-007481.md) | [1.3](/filings/0001171843-26-000136.md) | [1.3](/filings/0001171843-26-002340.md) | [1.1](/filings/0001171843-26-004548.md) | [1.3 d](/filings/0001171843-25-007481.md) | [1.2](/filings/0001171843-26-000136.md) | [1.2](/filings/0001171843-26-002340.md) | [1.2](/filings/0001171843-26-004548.md) |
| Operating income | $m | [2.5 d](/filings/0001171843-24-006440.md) | [1.4](/filings/0001171843-25-000165.md) | [2.2](/filings/0001171843-25-002130.md) | [1.5](/filings/0001171843-25-004413.md) | [2.8 d](/filings/0001171843-25-007481.md) | [1.1](/filings/0001171843-26-000136.md) | [(0.3)](/filings/0001171843-26-002340.md) | [0.9](/filings/0001171843-26-004548.md) | [0.9 d](/filings/0001171843-25-007481.md) | [0.9](/filings/0001171843-26-000136.md) | [0.4](/filings/0001171843-26-002340.md) | [0.5](/filings/0001171843-26-004548.md) |
| Interest expense | $m | [0.1 d](/filings/0001171843-24-006440.md) | [0.1](/filings/0001171843-25-000165.md) | [0.1](/filings/0001171843-25-002130.md) | [0.1](/filings/0001171843-24-003883.md) | [0.1 d](/filings/0001171843-24-006440.md) | [0.1](/filings/0001171843-25-000165.md) | [0.1](/filings/0001171843-25-002130.md) | [0.2](/filings/0001171843-26-004548.md) | [0.2 d](/filings/0001171843-25-007481.md) | [0.2](/filings/0001171843-26-000136.md) | [0.2](/filings/0001171843-26-002340.md) | [0.2](/filings/0001171843-26-004548.md) |
| Income tax | $m | [0.5 d](/filings/0001171843-24-006440.md) | [0.2](/filings/0001171843-25-000165.md) | [0.3](/filings/0001171843-25-002130.md) | [0.3](/filings/0001171843-25-004413.md) | [0.5 d](/filings/0001171843-25-007481.md) | [0.2](/filings/0001171843-26-000136.md) | [0.3](/filings/0001171843-26-002340.md) | [0.4](/filings/0001171843-26-004548.md) | [1.1 d](/filings/0001171843-25-007481.md) | [0.3](/filings/0001171843-26-000136.md) | [0.1](/filings/0001171843-26-002340.md) | [0.4](/filings/0001171843-26-004548.md) |
| Net income | $m | [0.9 d](/filings/0001171843-24-006440.md) | [0.9](/filings/0001171843-25-000165.md) | [1.7](/filings/0001171843-25-002130.md) | [1.0](/filings/0001171843-25-004413.md) | [1.8 d](/filings/0001171843-25-007481.md) | [0.6](/filings/0001171843-26-000136.md) | [0.4](/filings/0001171843-26-002340.md) | [0.1](/filings/0001171843-26-004548.md) | [(1.1) d](/filings/0001171843-25-007481.md) | [0.2](/filings/0001171843-26-000136.md) | [(0.0)](/filings/0001171843-26-002340.md) | [(0.3)](/filings/0001171843-26-004548.md) |
| Diluted EPS | $ per share | not reported | [0.09](/filings/0001171843-25-000165.md) | [0.17](/filings/0001171843-25-002130.md) | [0.10](/filings/0001171843-25-004413.md) | not reported | [0.06](/filings/0001171843-26-000136.md) | [0.04](/filings/0001171843-26-002340.md) | [0.01](/filings/0001171843-26-004548.md) | not reported | [0.03](/filings/0001171843-26-000136.md) | [0.00](/filings/0001171843-26-002340.md) | [(0.03)](/filings/0001171843-26-004548.md) |
| Basic EPS | $ per share | not reported | [0.09](/filings/0001171843-25-000165.md) | [0.18](/filings/0001171843-25-002130.md) | [0.10](/filings/0001171843-25-004413.md) | not reported | [0.06](/filings/0001171843-26-000136.md) | [0.05](/filings/0001171843-26-002340.md) | [0.01](/filings/0001171843-26-004548.md) | not reported | [0.03](/filings/0001171843-26-000136.md) | [0.00](/filings/0001171843-26-002340.md) | [(0.03)](/filings/0001171843-26-004548.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.4](/filings/0001171843-24-006440.md) | [6.1](/filings/0001171843-24-000207.md) | [4.8](/filings/0001171843-24-001955.md) | [5.8](/filings/0001171843-24-003883.md) | [5.0](/filings/0001171843-25-007481.md) | [5.6](/filings/0001171843-25-000165.md) | [5.1](/filings/0001171843-25-002130.md) | [6.8](/filings/0001171843-25-004413.md) | [7.3](/filings/0001171843-26-004548.md) | [6.4](/filings/0001171843-26-000136.md) | [6.5](/filings/0001171843-26-002340.md) | [7.3](/filings/0001171843-26-004548.md) |
| Current assets | $m | [39.7](/filings/0001171843-24-006440.md) | [38.3](/filings/0001171843-24-000207.md) | [37.3](/filings/0001171843-24-001955.md) | [37.9](/filings/0001171843-24-003883.md) | [41.6](/filings/0001171843-25-007481.md) | [40.3](/filings/0001171843-25-000165.md) | [39.6](/filings/0001171843-25-002130.md) | [42.6](/filings/0001171843-25-004413.md) | [44.3](/filings/0001171843-26-004548.md) | [44.6](/filings/0001171843-26-000136.md) | [45.2](/filings/0001171843-26-002340.md) | [47.8](/filings/0001171843-26-004548.md) |
| Total assets | $m | [89.3](/filings/0001171843-24-006440.md) | [88.8](/filings/0001171843-24-000207.md) | [87.3](/filings/0001171843-24-001955.md) | [89.3](/filings/0001171843-24-003883.md) | [94.7](/filings/0001171843-25-007481.md) | [94.0](/filings/0001171843-25-000165.md) | [93.7](/filings/0001171843-25-002130.md) | [99.3](/filings/0001171843-25-004413.md) | [103](/filings/0001171843-26-004548.md) | [104](/filings/0001171843-26-000136.md) | [105](/filings/0001171843-26-002340.md) | [107](/filings/0001171843-26-004548.md) |
| Current liabilities | $m | [16.7](/filings/0001171843-24-006440.md) | [15.9](/filings/0001171843-24-000207.md) | [13.4](/filings/0001171843-24-001955.md) | [14.8](/filings/0001171843-24-003883.md) | [17.9](/filings/0001171843-25-007481.md) | [18.1](/filings/0001171843-25-000165.md) | [18.2](/filings/0001171843-25-002130.md) | [20.9](/filings/0001171843-25-004413.md) | [23.9](/filings/0001171843-26-004548.md) | [25.2](/filings/0001171843-26-000136.md) | [25.0](/filings/0001171843-26-002340.md) | [27.8](/filings/0001171843-26-004548.md) |
| Shareholders' equity | $m | [70.7](/filings/0001171843-24-001955.md) | [71.0](/filings/0001171843-24-001955.md) | [68.4](/filings/0001171843-24-001955.md) | [68.9](/filings/0001171843-24-003883.md) | [71.2](/filings/0001171843-25-007481.md) | [70.2](/filings/0001171843-25-000165.md) | [69.7](/filings/0001171843-25-002130.md) | [72.4](/filings/0001171843-25-004413.md) | [72.1](/filings/0001171843-26-004548.md) | [72.4](/filings/0001171843-26-000136.md) | [73.3](/filings/0001171843-26-002340.md) | [72.8](/filings/0001171843-26-004548.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [2,035 d](/filings/0001171843-24-006440.md) | [3,077](/filings/0001171843-25-000165.md) | [2,566 d](/filings/0001171843-25-002130.md) | [1,941 d](/filings/0001171843-25-004413.md) | [(1,701) d](/filings/0001171843-25-007481.md) | [2,395](/filings/0001171843-26-000136.md) | [804 d](/filings/0001171843-26-002340.md) | [610 d](/filings/0001171843-26-004548.md) | [(1,365) d](/filings/0001171843-25-007481.md) | [342](/filings/0001171843-26-000136.md) | [(1,724) d](/filings/0001171843-26-002340.md) | [623 d](/filings/0001171843-26-004548.md) |
| Capital expenditure | $k | [640 d](/filings/0001171843-24-006440.md) | [391](/filings/0001171843-25-000165.md) | [1,053 d](/filings/0001171843-25-002130.md) | [1,071 d](/filings/0001171843-25-004413.md) | [(597) d](/filings/0001171843-25-007481.md) | [1,220](/filings/0001171843-26-000136.md) | [(511) d](/filings/0001171843-26-002340.md) | [781 d](/filings/0001171843-26-004548.md) | [36.4 d](/filings/0001171843-25-007481.md) | [822](/filings/0001171843-26-000136.md) | [185 d](/filings/0001171843-26-002340.md) | [46.5 d](/filings/0001171843-26-004548.md) |
| Dividends paid | $k | [657 d](/filings/0001171843-24-006440.md) | [660](/filings/0001171843-25-000165.md) | [660 d](/filings/0001171843-25-002130.md) | [661 d](/filings/0001171843-25-004413.md) | [662 d](/filings/0001171843-25-007481.md) | [663](/filings/0001171843-26-000136.md) | [663 d](/filings/0001171843-26-002340.md) | [94.7 d](/filings/0001171843-26-004548.md) | [94.7 d](/filings/0001171843-25-007481.md) | [94.8](/filings/0001171843-26-000136.md) | [94.9 d](/filings/0001171843-26-002340.md) | [0.0 d](/filings/0001171843-26-004548.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-11-30) | Q2 FY2023 (2023-02-28) | Q3 FY2023 (2023-05-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.7](/filings/0001171843-24-000207.md) | [9.7](/filings/0001171843-24-001955.md) | [9.6](/filings/0001171843-24-003883.md) | [9.7](/filings/0001171843-25-000165.md) | [9.7](/filings/0001171843-25-002130.md) | [10.0](/filings/0001171843-25-004413.md) | [9.8](/filings/0001171843-26-000136.md) | [9.8](/filings/0001171843-26-002340.md) | [9.5](/filings/0001171843-26-004548.md) | [9.5](/filings/0001171843-26-000136.md) | [9.5](/filings/0001171843-26-002340.md) | [9.5](/filings/0001171843-26-004548.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,496,439 at 2026-07-09, from the cover of the [10-Q filed 2026-07-09](/filings/0001171843-26-004548.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.